eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Journal's reviewers Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
5/2021
vol. 38
 
Share:
Share:
more
 
 
abstract:
Original paper

Therapeutic preferences and factors determining the use of inhaled corticosteroids with long-acting β2-agonists in patients with asthma and chronic obstructive pulmonary disease

Magdalena Olszanecka-Glinianowicz
1
,
Jerzy Chudek
2
,
Agnieszka Almgren-Rachtan
3

1.
Health Promotion and Obesity Management Unit, Department of Pathophysiology, Medical Faculty, Medical University of Silesia, Katowice, Poland
2.
Department of Internal Medicine and Oncological Chemotherapy, School of Medicine, Medical University of Silesia, Katowice, Poland
3.
Pharmacovigilance Department, Europharma, Katowice, Poland
Adv Dermatol Allergol 2021; XXXVIII (5): 752–760
Online publish date: 2020/10/16
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
Inhaled corticosteroids (ICS) and long-acting b2-agonists (LABA) are a part of standard therapy of bronchial asthma and chronic obstructive pulmonary disease (COPD).

Aim
Assessment of the therapeutic preferences and factors determining the choice of polytherapy with ICS and LABA in patients with asthma and COPD in daily clinical practice.

Material and methods
This multicentre, open-label, post-marketing observational survey was performed nation-wide with the participation of 245 doctors and 13,800 patients with asthma or COPD on polytherapy with ICS and LABA. The study questionnaire included two parts: concerning doctors’ preferences in the use of ICS and LABA and their prescription in patients as well as efficacy and tolerance of inhaled drugs during two consecutive visits.

Results
The study doctors frequently declared a choice of polytherapy with formoterol and fluticasone in patients with asthma and COPD. The most important factors supporting the choice of ICS and LABA, declared by doctors, were safety and efficacy. ICS and LABA polytherapy with formoterol and fluticasone was used in 71.0% of patients with asthma and 81.4% with COPD. The most important factors explaining the choice of this drug combination were safety (75.3% and 72.5%, respectively) and efficacy (75.2% and 71.9%, respectively).

Conclusions
Formoterol and fluticasone polytherapy is frequently chosen by Polish physicians in the treatment of asthma and COPD due to its high efficacy and safety. In accordance with doctors’ declaration, in the study group this therapy was characterized by the highest effectiveness and the best tolerance.

keywords:

asthma, chronic obstructive pulmonary disease, inhaled corticosteroids, long-acting b2-agonists, therapeutic preferences, efficacy, safety

Quick links
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.